José Luís Poveda

1.5k total citations
90 papers, 922 citations indexed

About

José Luís Poveda is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, José Luís Poveda has authored 90 papers receiving a total of 922 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 18 papers in Oncology and 15 papers in Public Health, Environmental and Occupational Health. Recurrent topics in José Luís Poveda's work include Acute Myeloid Leukemia Research (16 papers), Acute Lymphoblastic Leukemia research (12 papers) and Drug Transport and Resistance Mechanisms (11 papers). José Luís Poveda is often cited by papers focused on Acute Myeloid Leukemia Research (16 papers), Acute Lymphoblastic Leukemia research (12 papers) and Drug Transport and Resistance Mechanisms (11 papers). José Luís Poveda collaborates with scholars based in Spain, Chile and United Kingdom. José Luís Poveda's co-authors include Virginia Bosó, Salvador F. Aliño, María José Herrero, Juan Eduardo Megías‐Vericat, Luis Rojas, Pau Montesinos, Miguel Á. Sanz, David Martínez‐Cuadrón, Eva Romá and Máximo Vento and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Scientific Reports.

In The Last Decade

José Luís Poveda

83 papers receiving 903 citations

Peers

Countries citing papers authored by José Luís Poveda

Since Specialization

Citations

This map shows the geographic impact of José Luís Poveda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by José Luís Poveda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites José Luís Poveda more than expected).

Fields of papers citing papers by José Luís Poveda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by José Luís Poveda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by José Luís Poveda. The network helps show where José Luís Poveda may publish in the future.

Co-authorship network of co-authors of José Luís Poveda

This figure shows the co-authorship network connecting the top 25 collaborators of José Luís Poveda. A scholar is included among the top collaborators of José Luís Poveda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with José Luís Poveda. José Luís Poveda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review 2025 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), Juan Eduardo Megías‐Vericat, (unknown), (unknown), Pilar Nos, (unknown), José Luís Poveda	2
2	Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety 2024 ·Antibiotics ·María Martín Cerezuela, (unknown), (unknown), (unknown), (unknown), (unknown), José‐Esteban Peris, R. Gimeno, Álvaro Castellanos-Ortega, José Luís Poveda, Paula Ramírez	3
3	Value contribution of etranacogene dezaparvovec gene therapy in moderately severe and severe haemophilia B through multi‐criteria decision analysis 2024 ·Haemophilia ·(unknown), Xavier Badía, (unknown), Víctor Jiménez‐Yuste, (unknown), Ramiro Núñez, José Luís Poveda, José Luís Trillo, (unknown)	1
4	Determining value in the treatment of activated PI3Kδ syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), Laia Alsina, Eduardo López Granados, Olaf Neth, José Luís Poveda, Jacques G. Rivière, Carlos Rodríguez‐Gallego, (unknown), (unknown), (unknown)	1
5	Contribución de valor de olipudase alfa en el tratamiento de las manifestaciones no relacionadas con el SNC del déficit de esfingomielinasa ácida mediante análisis de decisión multicriterio 2023 ·(unknown), (unknown), Antonio González‐Meneses, (unknown), José Luís Poveda, José Luís Trillo, (unknown), (unknown), Ariadna Giró‐Perafita, Xavier Badía	1
6	ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requiring a PASS would be more likely to be reimbursed in Spain 2023 ·Orphanet Journal of Rare Diseases ·José Luís Poveda, (unknown), (unknown), Xavier Badía	1
7	Value contribution of olipudase alfa therapy for the management of the non-CNS manifestations of acid sphingomyelinase deficiency by multi-criteria decision analysis 2023 ·(unknown), (unknown), Antonio González‐Meneses, (unknown), José Luís Poveda, José Luís Trillo, (unknown), (unknown), Ariadna Giró‐Perafita, Xavier Badía	1
8	Healthcare Resource Utilization among Patients between 60–75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study 2022 ·Cancers ·(unknown), Juan Eduardo Megías‐Vericat, (unknown), Blanca Boluda, Isabel Cano, (unknown), Rebeca Rodríguez‐Veiga, (unknown), Claudia Sargas, Miguel Á. Sanz, (unknown), Eduardo López Briz, José Luís Poveda, Javier de la Rubia, Pau Montesinos, David Martínez‐Cuadrón	2
9	The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis 2022 ·Epilepsy & Behavior ·António Gil‐Nagel, Mercè Falip, Rocío Sánchez‐Carpintero, (unknown), José Luís Poveda, (unknown), Elena Cardenal‐Muñoz, (unknown), (unknown), (unknown), José Luís Trillo, (unknown), (unknown)	14
10	Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule 2019 ·Acta Paediatrica ·(unknown), (unknown), Iris Usach, Máximo Vento, José Luís Poveda, José‐Esteban Peris, Víctor Mangas‐Sanjuán	8
11	Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis 2019 ·SHILAP Revista de lepidopterología ·María Román, (unknown), (unknown), José Luís Poveda, (unknown), Amparo Santamaría, José Luís Trillo, (unknown), Xavier Badía	4
12	PRO115 DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN 2019 ·Value in Health ·José Luís Poveda, (unknown), (unknown), (unknown), (unknown), Encarna Guillén‐Navarro, Isidro Jarque, (unknown), Isidro Vitoria	0
13	Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project 2018 ·BMJ Open ·Joan Bladé, Miguel Ángel Calleja, Juan José Lahuerta, José Luís Poveda, Héctor D. de Paz, Luís Lizán	5
14	PSY155 - DETERMINING THE VALUE OF EMICIZUMAB (HEMLIBRA®) FOR THE PROPHYLAXIS TREATMENT OF HAEMOPHILIA A PATIENTS WITH INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA) 2018 ·Value in Health ·(unknown), (unknown), (unknown), José Luís Poveda, (unknown), Amparo Santamaría, (unknown), (unknown), Xavier Badía	1
15	Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection 2017 ·American Journal of Transplantation ·Amparó Solé, (unknown), (unknown), Enrique Cases Viedma, (unknown), José Luís Poveda, (unknown), Javier Pemán	17
16	Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report 2017 ·Journal of Clinical Pharmacy and Therapeutics ·Jesús Ruiz Ramos, (unknown), (unknown), (unknown), José Luís Poveda	4
17	Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients 2017 ·Blood Purification ·Jesús Ruiz Ramos, (unknown), Mónica Gordón, (unknown), (unknown), (unknown), José Luís Poveda, Álvaro Castellanos-Ortega, Paula Ramírez	3
18	Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies 2015 ·The Pharmacogenomics Journal ·Juan Eduardo Megías‐Vericat, Luis Rojas, María José Herrero, Virginia Bosó, Pau Montesinos, Federico Moscardó, José Luís Poveda, Miguel Á. Sanz, Salvador F. Aliño	26
19	Genotype and Allele Frequencies of Drug-Metabolizing Enzymes and Drug Transporter Genes Affecting Immunosuppressants in the Spanish White Population 2013 ·Therapeutic Drug Monitoring ·Virginia Bosó, María José Herrero, (unknown), Juan Carlos Galán, Luís Almenar, Ignacio Sánchez‐Lázaro, Jaime Sánchez‐Plumed, (unknown), M. Prieto, María I. García, A. Pastor, Amparó Solé, José Luís Poveda, Salvador F. Aliño	16
20	Cluster of Leptospirosis Cases Among Children in France 2002 ·European Journal of Clinical Microbiology & Infectious Diseases ·Natacha Sertour, (unknown), José Luís Poveda, A Perra, G. Baranton, D. Postic	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact